Clinical trial
A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular…
NCT00234520 · Ipsen, Industry · Completed
Key facts
| NCT number | NCT00234520 |
|---|---|
| Title | A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide |
| Official title | A Multicentre Prospective Controlled Observer Blinded Cohort Study in Patients With Acromegaly to Evaluate the Risk of Cardiac Valvular Regurgitation in Patients Treated With Lanreotide Relative to Patients Treated With Octreotide |
| Lead sponsor | Ipsen, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Acromegaly |
| Enrollment | 225 |
| Start date | May 1, 2003 |
| Primary completion | Feb 18, 2005 |
| Completion | Feb 18, 2005 |
| First posted | Oct 7, 2005 |
| Last update posted | Aug 2, 2019 |
| Countries | Belgium, Czechia, Denmark, France, Hungary, Italy, Poland, Spain, Sweden, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: